Article
Multidisciplinary Sciences
Tyng-Yuan Jang, Yu-Ju Wei, Ta-Wei Liu, Ming-Lun Yeh, Shu-Fen Liu, Cheng-Ting Hsu, Po-Yao Hsu, Yi-Hung Lin, Po-Cheng Liang, Meng-Hsuan Hsieh, Yu-Min Ko, Yi-Shan Tsai, Kuan-Yu Chen, Ching-Chih Lin, Pei-Chien Tsai, Shu-Chi Wang, Ching- Huang, Zu-Yau Lin, Shinn-Cherng Chen, Wan-Long Chuang, Jee-Fu Huang, Chia-Yen Dai, Chung-Feng Huang, Ming-Lung Yu
Summary: This study found that hepatitis D virus (HDV) viremia plays a crucial role in the development of hepatocellular carcinoma (HCC) in chronic hepatitis B patients undergoing nucleotide/nucleoside analogues (NAs) therapy, particularly in cirrhotic patients.
SCIENTIFIC REPORTS
(2021)
Article
Multidisciplinary Sciences
Satoru Joshita, Masao Ota, Hiroyuki Kobayashi, Shun-ichi Wakabayashi, Yuki Yamashita, Ayumi Sugiura, Tomoo Yamazaki, Eiji Tanaka, Takeji Umemura
Summary: This study revealed significant associations of KIR/HLA with HCC development (KIR2DS3) and freedom from NUC therapy (KIR3DL1/HLA-Bw4) in HBV patients, although larger case studies are needed for statistical purposes.
SCIENTIFIC REPORTS
(2021)
Review
Medicine, General & Internal
Wen-Juei Jeng, George Papatheodoridis, Anna S. F. Lok
Summary: Hepatitis B virus (HBV) infection is a significant global public health problem, with a large number of chronic infections and deaths reported every year. Diagnosis of HBV infection requires serological testing for specific antibodies. Treatment mainly focuses on preventing liver disease progression and development of complications. Efforts are being made to develop new therapies that aim for a functional cure, while prevention strategies include universal vaccination and improved screening and diagnosis. Achieving the goal of eliminating HBV infection by 2030 requires a comprehensive approach.
Article
Cell Biology
Jamie A. Sugrue, Celine Posseme, Ziyang Tan, Christian Pou, Bruno Charbit, Vincent Bondet, Nollaig M. Bourke, Petter Brodin, Darragh Duffy, Cliona O'Farrelly
Summary: This study found that some individuals can resist HCV infection despite exposure to the virus, possibly due to enhanced TLR3-type I interferon response and increased inflammatory cytokine production.
CELL REPORTS MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Jill Koshiol, Ilona Argirion, Zhiwei Liu, Tram Kim Lam, Thomas R. O'Brien, Kelly Yu, Katherine A. McGlynn, Jessica L. Petrick, Ligia Pinto, Chien-jen Chen, Allan Hildesheim, Ruth M. Pfeiffer, Mei-Hsuan Lee, Hwai- Yang
Summary: This study evaluated the relationship between immunologic markers and HCC risk, finding that ICAM-1 was associated with increased risk of HCC. Additionally, four additional proteins were identified to be associated with HBV- and HCV-related HCC.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Gastroenterology & Hepatology
Daniel Q. Huang, Xiaohe Li, Michael H. Le, An K. Le, Yee Hui Yeo, Huy N. Trinh, Jian Zhang, Jiayi Li, Christopher Wong, Clifford Wong, Ramsey C. Cheung, Hwai- Yang, Mindie H. Nguyen
Summary: This study found that a significant proportion of patients with chronic hepatitis B are in the indeterminate phase. Of these patients, around half remain indeterminate and one-fifth transition to the immune active phase. The risk of hepatocellular carcinoma is significantly higher in persistently indeterminate CHB patients, particularly in those aged 45 years and older.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Pediatrics
Simon C. Ling, Hsing-Hua S. Lin, Karen F. Murray, Philip Rosenthal, Douglas Mogul, Norberto Rodriguez-Baez, Sarah Jane Schwarzenberg, Jeffrey Teckman, Kathleen B. Schwarz
Summary: The study found that many children with chronic HBV infection in the US and Canada remain at risk of progressive liver disease due to active hepatitis, but major clinical outcomes such as cirrhosis, cancer, and death were rare. Many children who met treatment criteria did not receive treatment.
JOURNAL OF PEDIATRICS
(2021)
Review
Microbiology
Zeyu Zhao, Meijie Chu, Yichao Guo, Shiting Yang, Guzainuer Abudurusuli, Roger Frutos, Tianmu Chen
Summary: Hepatitis C poses a significant burden in China and requires strategic surveillance, management, and treatment programs. The disease has a varied geographical distribution with certain regions and populations experiencing a higher disease burden. It is crucial to improve diagnosis rates in high-risk populations and asymptomatic individuals, identify secondary infections, especially in those co-infected with HIV, and enhance access to direct antiviral agents (DAAs) to improve cure rates.
FRONTIERS IN MICROBIOLOGY
(2022)
Article
Medicine, General & Internal
Lars T. Fadnes, Christer Frode Aas, Jorn Henrik Vold, Rafael Alexander Leiva, Christian Ohldieck, Fatemeh Chalabianloo, Svetlana Skurtveit, Ole Jorgen Lygren, Olav Dalgard, Peter Vickerman, Havard Midgard, Else-Marie Loberg, Kjell Arne Johansson
Summary: This study found that integrated treatment for chronic HCV infection among people who inject drugs was more effective in terms of time-to-treatment initiation and achieving sustained virologic response compared to standard treatment. It also showed comparable SVR rates among those who initiated treatment. Scaling up integrated treatment models could be crucial in the elimination of HCV.
Editorial Material
Biochemistry & Molecular Biology
T. Jake Liang
Summary: New strategies utilizing nucleic acid technologies are being explored for the treatment of chronic hepatitis B, with a pilot clinical study of antisense oligonucleotide treatment demonstrating the potential promise of this approach.
Article
Gastroenterology & Hepatology
Federico Guillermo Villamil, Nancy Elena Massenzio, Patricia Cristina Bare, Paula Andrea Cocco, Fernando Mario Cairo, Gaston Rafael Picchio
Summary: This study evaluated the impact of HCV screening, clinical evaluation, and antiviral therapy on the elimination of HCV. After 20 years of follow-up, there was a significant decrease in the prevalence of HCV in the population, and the success rate of antiviral therapy was high.
ANNALS OF HEPATOLOGY
(2022)
Review
Virology
Minghang Wang, Zongdi Feng
Summary: Hepatitis A virus (HAV) infection is a common cause of acute viral hepatitis, and while virus-specific cytotoxic T cells were previously believed to be responsible for liver injury, recent evidence suggests that natural killer (NK) cells, NKT cells, and even non-HAV-specific CD8(+) T cells may also contribute to liver damage. Intrinsic death of virus-infected hepatocytes and genetic variations in host factors have also been linked to hepatitis A severity. Understanding these mechanisms could improve diagnosis and treatment of diseases associated with HAV infection.
Review
Immunology
Amir M. Mohareb, Anne F. Liu, Arthur Y. Kim, Patrick A. Coffie, Menan Gerard Kouame, Kenneth A. Freedberg, Anders Boyd, Emily P. Hyle
Summary: Spontaneous loss of hepatitis B e antigen (HBeAg) occurs at a rate of 6.46/100 person-years (PYs) among untreated individuals with chronic HBV. The incidence rate of spontaneous HBeAg loss varies by age and geographic region.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Oncology
Yuan-Hung Kuo, Tzu-Hsin Huang, Jing-Houng Wang, Yen-Yang Chen, Ming-Chao Tsai, Yen-Hao Chen, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Chao-Hung Hung
Summary: This study confirms that while HCV-HCC patients may have a better prognosis when using sorafenib, there is no difference in prognosis between HBV-HCC and HCV-HCC patients when it comes to controlling viral load. The control of viral load is associated with prognosis, while HBV or HCV infection is not.
Article
Pediatrics
Eric W. Hall, Lakshmi Panagiotakopoulos, Carolyn Wester, Noele Nelson, Amy L. Sandul
Summary: This study determines the optimal testing strategy for identifying children with perinatally acquired HCV infection, showing that testing infants at 2-6 months with a single HCV RNA test reduces costs and improves health outcomes.
JOURNAL OF PEDIATRICS
(2023)
